Sucampo Pharma (SCMP) Posts Q3 Break Even EPS; Misses by 3c
More News related to SCMP
- Sucampo Pharma (SCMP) Presents Additional Clinical Data for Lubiprostone
- Sucampo Announces Lubiprostone Data Presented at GASTRO 2009 UEGF/WCOG
- Sucampo Pharma (SCMP) Subsidiary Granted Marketing Authorization for Amitiza in Switzerland
- Sucampo Receives Marketing Authorization for Amitiza(R) in Switzerland for Treatment of Chronic Idiopathic Constipation
- Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at Credit Suisse Conference
More News related to Earnings
- Hydrogenics Resumes Trading Under NASDAQ Symbol "HYGS"
- Varian Medical (VAR) to Highlight its New Range of Detectors at Annual RSNA Meeting in Chicago
- Manulife (MFC) Confirms No Exposure to Dubai World
- Activision's (ATVI) Call of Duty Amasses $3 Billion in Global Sales
- Seiko Epson to Transfer Sales Function of Small and Medium-Sized TFT LCD Business to Sony (SNE)
Sucampo Pharmaceuticals, Inc (NASDAQ: SCMP) reports Q3 EPS of $0.00, versus the analyst estimate of $0.03. Revenue for the quarter was $16.40 million, which compares to the estimate of $18.37 million.
Related Categories
EarningsStocks Mentioned
-0.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
